14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VRDN vs RAPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VRDN carries a Unified Composite Score of 36.8/100 (SELL) at $30.36 (1.0x Forward P/E, -1781.4% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. 0.0% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRDN vs RAPT. Trailing 12-month operating profitability (VRDN -1781.4% vs RAPT 0.0%) and valuation multiples (VRDN 1.0x vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VRDN vs RAPT Key Questions & Quantitative Answers
As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VRDN carries a Unified Composite Score of 36.8/100 (SELL) at $30.36 (1.0x Forward P/E, -1781.4% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. 0.0% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY).
VRDN leads the Growth & Scale pillar: VRDN posts -63.5% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (N/A gross margin, -1781.4% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VRDN generates $26M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, VRDN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.
VRDN screens cheaper on headline valuation multiples. VRDN trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and 134.2x EV/Revenue (unreported FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRDN (-83.7% ROE) versus RAPT (-85.4% ROE) capital efficiency.
In options market volatility and institutional positioning, VRDN carries 87.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.13β · 65% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.